Solaraze

Contusions, Pain, Photophobia + 54 more

Treatment

10 FDA approvals

20 Active Studies for Solaraze

What is Solaraze

Diclofenac

The Generic name of this drug

Treatment Summary

Diclofenac is a type of medication used to reduce pain and inflammation. It belongs to a class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs work by blocking the enzymes that produce prostaglandins, which cause inflammation and pain. Diclofenac is a popular choice for treating pain and inflammation from a variety of causes. It is often taken in combination with misoprostol to prevent stomach ulcers caused by the drug. Diclofenac was approved by the FDA in 1988 and is sold under the brand name Voltaren.

Voltaren

is the brand name

image of different drug pills on a surface

Solaraze Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voltaren

Diclofenac

1988

767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Osteoarthritis of the Knee and Pain .

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Pain

Helps manage Pain

Postoperative Inflammatory Response

Chronic Pain

Helps manage Pain

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Stomach Ulcer

Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Rheumatoid Arthritis

Cataract Surgery

Effectiveness

How Solaraze Affects Patients

Diclofenac helps reduce inflammation, pain, and fever. However, it can also cause stomach ulcers by reducing the amount of protective mucus in the stomach.

How Solaraze works in the body

Diclofenac works to reduce pain and inflammation in the body by inhibiting the production of prostaglandins. Prostaglandins are molecules that have wide-ranging effects on pain and inflammation. They make nerves more sensitive, reduce the threshold for action potentials, and make blood vessels wider. In the long term, they reduce immune responses. Prostaglandins also activate thermoregulatory neurons in the brain, which increases body temperature and causes a fever. By preventing the production of prostaglandins, diclofenac combats all of these effects.

When to interrupt dosage

The recommended measure of Solaraze is contingent upon the identified ailment, including Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The amount likewise fluctuates as per the mode of delivery (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) featured in the table beneath.

Condition

Dosage

Administration

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Photophobia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Muscle Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Rheumatoid Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Osteoarthritis of the Knee

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Contusions

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Fever

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Conjunctivitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Surgery, Dental

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Wounds, Nonpenetrating

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

perioperative miosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Sprains and Strains

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Rheumatism

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Musculoskeletal System

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Postoperative Inflammatory Response

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Postoperative

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Liquid - Ophthalmic, Suppository, Rectal, Suppository - Rectal, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated - Oral, Tablet, coated, Drug delivery system - Topical, Drug delivery system

Warnings

Solaraze Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Heart failure

Do Not Combine

Crohn's Disease

Do Not Combine

recent history of anal bleeding

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Gastritis

Do Not Combine

inflammatory lesions of the Rectum

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

active Gastrointestinal Perforation

Do Not Combine

Duodenal Ulcer

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Ulcerative Colitis

Do Not Combine

Liver Diseases

Do Not Combine

Stroke

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Hematochezia

Do Not Combine

Kidney Failure

Do Not Combine

Kidney Failure

Do Not Combine

Anus

Do Not Combine

Ulcer

Do Not Combine

damaged skin

Do Not Combine

Gastric ulcer

Do Not Combine

Peptic Ulcer

Do Not Combine

Hyperkalemia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Diclofenac may interact with Pulse Frequency

There are 20 known major drug interactions with Solaraze.

Common Solaraze Drug Interactions

Drug Name

Risk Level

Description

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Diclofenac.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Diclofenac.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Diclofenac.

Solaraze Toxicity & Overdose Risk

Overdosing on Voltaren can lead to symptoms such as fatigue, nausea, vomiting, upper abdominal pain, and bleeding from the digestive tract. In rare cases, patients may experience high blood pressure, kidney damage or failure, hypoventilation, or coma. Treatments for Voltaren overdose include inducing vomiting and activated charcoal, as long as the overdose occurred within the last 4 hours.

image of a doctor in a lab doing drug, clinical research

Solaraze Novel Uses: Which Conditions Have a Clinical Trial Featuring Solaraze?

491 active clinical trials are currently examining the potential of Solaraze to ameliorate Inflammation, argon laser trabeculoplasty and Osteoarthritis of the Knee.

Condition

Clinical Trials

Trial Phases

Inflammation

59 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3

Osteoarthritis of the Knee

78 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Chronic Pain

118 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Rheumatoid Arthritis

56 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Postoperative Pain

20 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 1, Phase 3

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Muscle Pain

2 Actively Recruiting

Phase 4, Phase 2

Conjunctivitis

0 Actively Recruiting

Musculoskeletal System

1 Actively Recruiting

Not Applicable

corneal refractive surgery

0 Actively Recruiting

Postoperative Inflammatory Response

0 Actively Recruiting

Photophobia

5 Actively Recruiting

Not Applicable

Pain

2 Actively Recruiting

Not Applicable

Stomach Ulcer

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Juvenile arthritis

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

radial keratotomy

0 Actively Recruiting

Joints

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Acute Coryza

0 Actively Recruiting

Solaraze Reviews: What are patients saying about Solaraze?

5

Patient Review

11/27/2019

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I've been using this treatment for a month now and all the rough patches of keratosis on my face are gone. I've used it before for 90 days with the same success; however, after a couple months the sun damage begins to reappear. Need to check with doctor how often I can retreat with this product.

5

Patient Review

1/6/2017

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I followed my dermatologist's orders and used this for three months on my face. It was completely successful, though I did have to take some antihistamines for the severe irritation about halfway through. The next round of treatment (on my arms, chest, and legs) is not something I'm looking forward to but the results last long enough that it's worth it to me.

4

Patient Review

3/1/2022

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I've used Solaraze for 90 days now and it seems to have worked well! The only side effect I experienced was that my white hair turned yellow blonde. Not sure if this is common or not, but figured I'd mention it just in case.

4

Patient Review

9/16/2016

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I stuck with this treatment for two months, as it took that long to see any real results. But now the area where I was experiencing problems appears to have healed completely!

3.3

Patient Review

4/7/2014

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

Shortly after using this treatment on both of my forearms, I developed nickel-sized sores that took several weeks to heal. The sores also killed the pigment in my skin, so now there are white blotches on both of my forearms. I wish I had been warned about this potential side effect ahead of time!

3

Patient Review

8/27/2022

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I'm still seeing blemishes, despite using this product twice daily as directed.

2.7

Patient Review

1/1/2013

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

Unfortunately, I had a very negative reaction to this treatment. Three weeks in, I developed an intense itching rash with swelling and pustules. Additionally, my eyes swelled shut and I had blood and pus on my pillow. I had to go to emergency care and take steroids and antihistamines. I also needed antibiotics for a developing infection. So be careful if you have sensitive skin - I wasn't warned by the physician about this possibility.

2.7

Patient Review

11/9/2021

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I found that the cream made me anxious and gave me bad dreams, so I stopped using it before the recommended time was up. My mental health is more important to me than following the instructions on this medication. Thankfully, my anxiety levels returned to normal as soon as I stopped using Solarize.

2.3

Patient Review

11/30/2012

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

Solaraze did nothing for me except give me pimples and make my existing tinnitus worse.

2

Patient Review

8/30/2013

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I used this gel for four weeks and unfortunately started developing red patches, sores, and itchiness around my upper lip and nose. I'm discontinuing use in this area and hopefully it will heal without any scars. The other areas on my face healed well though.

2

Patient Review

4/10/2019

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

Unfortunately, I had a severe allergic reaction to this treatment. My face was swollen and covered in scabs and it was very itchy. I ended up having to go to the emergency room.

1.7

Patient Review

8/4/2014

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

I was diagnosed with actinic keratosis and prescribed solaraze. I used it for two weeks, but my rash and dry skin area increased. So, I went back to the doctor; they said it showed that it was working... One week later, I developed a blister on my lip and lowered eyelid ballooned up—my eye was almost shut. The third doctor told me to stop using it and prescribed a moisturising cream.

1.7

Patient Review

10/11/2013

Solaraze for Roughened Red Patches of Skin due to Sun Exposure

This product is way too expensive and didn't work at all.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about solaraze

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Solaraze do to your skin?

"The drug Solaraze works by destroying unstable skin cells and causing the immune system to repair the damaged skin. It contains a non-steroidal anti-inflammatory called Diclofenac, and another topical ingredient called hyaluronic acid (which helps tissue penetration of the drug into active sites)."

Answered by AI

What is Solaraze gel used to treat?

"Solaraze is a dermatological gel that is used to treat a skin problem known as actinic or solar keratosis. Solar keratosis is a skin condition that is caused by long-term sun exposure. If you are allergic to diclofenac or any of the ingredients of this medicine, you should not use Solaraze gel."

Answered by AI

How long should you use Solaraze for?

"Before using the medication, wash and dry your hands. Apply a thin layer of the medication to the affected skin, rub it in well, and do this 2 times every day. In most cases, you will need to do this for 60 to 90 days."

Answered by AI

Does Solaraze require prescription?

"Solaraze is a cream that is used to treat warts that have grown on sun-exposed areas of the body. It may be used alone or with other medications. Solaraze belongs to a class of drugs called Topical Skin Products."

Answered by AI

Clinical Trials for Solaraze

Image of UCI Health Susan Samueli Integrative Health Institute in Irvine, United States.

Biofield Therapy for Cancer

18+
All Sexes
Irvine, CA

Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms. The purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care. The secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement. Lastly, the third aim is to explore participants' experiences with Reiki through guided interviews. Participants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups: Immediate Reiki Group: If participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience. Waitlist Group: If they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience. The investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.

Recruiting
Has No Placebo

UCI Health Susan Samueli Integrative Health Institute (+1 Sites)

Have you considered Solaraze clinical trials?

We made a collection of clinical trials featuring Solaraze, we think they might fit your search criteria.
Go to Trials
Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Image of Hopital general de Montreal in Montreal, Canada.

Nurse-led Telehealth for Rheumatoid Arthritis

18+
All Sexes
Montreal, Canada

Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology. The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable. This new approach involves nurses helping patients check their own health from home using an online platform. 104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages. This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.

Waitlist Available
Has No Placebo

Hopital general de Montreal (+3 Sites)

Laetitia Michou, MD PhD

Image of Resilient Roots: Functional Medicine in Charlottesville, United States.

Ketogenic and Carnivore Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

18 - 64
All Sexes
Charlottesville, VA

This study is a randomized controlled clinical trial evaluating whether two therapeutic dietary approaches - a ketogenic diet and a carnivore (lion) diet - can improve quality of life, reduce symptoms, and influence measures of disease activity in adults with inflammatory bowel disease \[ulcerative colitis and Crohn's disease\] (IBD) or rheumatoid arthritis (RA). Participants will be randomized into one of three groups: 1) Ketogenic Diet, 2) Carnivore (Lion) Diet or 3) Wait-List Control. Participants randomized to a dietary group (ketogenic diet or carnivore diet) will be provided guidance on their specific dietary therapy and answer questions about their symptoms and quality of life at different intervals over a 24 week period. Participants will also complete laboratory testing at different intervals to assess for changes in nutritional status, cardiometabolic health and markers of immune activation and inflammation. Participants initially placed on the wait-list group will be asked similar questions about their symptoms and quality of life and complete the same laboratory testing as participants in a dietary group. Participants on the wait list will then be compared to participants following a specific dietary pattern to assess for any differences between the 2 groups. After 12 weeks, participants on the wait list will be randomized to a dietary group (ketogenic diet or carnivore diet) and followed in a similar fashion for an additional 12 week period.

Recruiting
Has No Placebo

Resilient Roots: Functional Medicine

Robert D Abbott, MD

Have you considered Solaraze clinical trials?

We made a collection of clinical trials featuring Solaraze, we think they might fit your search criteria.
Go to Trials
Image of University of California, Riverside in Riverside, United States.

Acetazolamide for Altitude Sickness

18 - 65
All Sexes
Riverside, CA

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Phase < 1
Waitlist Available

University of California, Riverside

Image of Marquette University in Milwaukee, United States.

Exercise for Pain

35 - 65
All Sexes
Milwaukee, WI

The goal of this clinical trial is to determine how male and female former athletes experience pain and respond to moderate-intensity exercise (strength versus aerobic) compared with both current master's athletes and nonathletes. The main questions this study aims to address are: 1. How do former athletes, master's athletes, and nonathletes experience pain? 2. How do different types of moderate-intensity exercise (strength versus aerobic exercise) influence pain in former athletes, master's athletes, and nonathletes? Participants will complete 3 different testing sessions: 1. Baseline testing including assessments of strength, cardiorespiratory fitness, and pain; 2. Strength exercise: pain assessments will occur before and after moderate-intensity strength training exercise; 3. Aerobic exercise: pain assessments will occur before and after moderate-intensity aerobic exercise. There will be a washout period of approximately one week or greater between each of the three different testing sessions. The order of conditions (strength versus aerobic exercise) will be randomized (crossover randomized trial design).

Recruiting
Has No Placebo

Marquette University

Jacob J Capin, DPT, PhD

Have you considered Solaraze clinical trials?

We made a collection of clinical trials featuring Solaraze, we think they might fit your search criteria.
Go to Trials